Intra-Cellular Therapies. has been granted a patent for pharmaceutical capsules containing lumateperone, either in its free form or as a pharmaceutically acceptable salt. The patent covers the manufacturing processes and methods for using these capsules in disease treatment or prevention. GlobalData’s report on Intra-Cellular Therapies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Intra-Cellular Therapies, Peptide pharmacophores was a key innovation area identified from patents. Intra-Cellular Therapies's grant share as of July 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12070459B2 describes a pharmaceutical capsule designed for oral administration, primarily containing lumateperone in solid crystal form. The claims detail various formulations of the capsule, which may include additional components such as colorants, mannitol, croscarmellose sodium, talc, and magnesium stearate. The patent specifies the proportions of these ingredients, with lumateperone comprising 10 to 30% by weight, and mannitol making up the majority of the capsule's content. The capsule is designed to dissolve effectively in an acidic environment, achieving at least 85% dissolution in 15 minutes. Furthermore, the patent outlines specific characteristics of the lumateperone crystals, including their particle size and X-ray powder diffraction patterns.
Additionally, the patent claims a method for treating various diseases and disorders associated with serotonin and dopamine receptor signaling pathways, including conditions such as depression, schizophrenia, and anxiety disorders. The administration of a single capsule under fasting conditions is reported to yield specific pharmacokinetic parameters, including a mean maximal plasma concentration (Cmax) of lumateperone and its metabolites, as well as the time to reach this concentration (Tmax). The patent also provides detailed information on the expected plasma metabolite levels and their ratios relative to lumateperone, indicating the potential therapeutic effects of the capsule formulation. Overall, the patent presents a comprehensive formulation and method for utilizing lumateperone in treating a range of psychiatric and neurological conditions.
To know more about GlobalData’s detailed insights on Intra-Cellular Therapies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
